Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis

In the present report, we have described the clinical course of 34 adult patients who had received blinatumomab or inotuzumab ozogamicin for relapsed or refractory acute lymphoblastic leukemia. Both agents induced high rates of molecular complete remission, with manageable toxicity profiles, allowing 80% of transplantable patients to proceed to allogeneic stem cell transplantation. These data suggest high efficacy and safety for both drugs in a bridge-to-transplantation setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research